Comparative Pharmacology
Head-to-head clinical analysis: LOTRONEX versus SANCUSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRONEX versus SANCUSO.
LOTRONEX vs SANCUSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin action in the GI tract, reducing intestinal motility and visceral hypersensitivity.
Granisetron is a selective 5-HT3 receptor antagonist. It blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) of the area postrema and on peripheral vagal nerve terminals, thereby inhibiting the vomiting reflex.
1 mg orally once daily for 4 weeks, then may increase to 1 mg twice daily if tolerated; maximum 1 mg twice daily.
3.1 mg patch applied to upper outer arm every 24 hours; applied 24-48 hours before chemotherapy and left on for 24 hours after chemotherapy completion.
None Documented
None Documented
The terminal elimination half-life is approximately 1.5 to 2 hours in healthy individuals. In patients with hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 25 hours following transdermal application. This long half-life supports the 72-hour dosing interval of the transdermal patch.
Alosetron is primarily eliminated via hepatic metabolism with subsequent renal excretion of metabolites. Approximately 73% of a dose is recovered in urine (mostly metabolites) and 24% in feces.
Approximately 95% of the dose is metabolized, with <5% excreted unchanged in urine. Metabolites are eliminated primarily via feces (about 70%) and urine (about 25%).
Category C
Category C
5-HT3 Receptor Antagonist
5-HT3 Receptor Antagonist